Nonalcoholic Steatohepatitis: Epidemiology, Screening, Risk Assessment, Diagnosis, and Management

  • Author: Philip N. Newsome, PhD, FRCPE (More Info)
  • Editor In Chief: Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
  • Last Reviewed: 8/23/19 (What's New)

Summary

  • For pharmacologic management of patients with NASH, the AASLD and EASL recommend considering use of pioglitazone and/or vitamin E[AASLD 2018; EASL 2016]
    • Pioglitazone has been associated with improved steatohepatitis in individuals with NASH with and without T2DM, although its clinical use is tempered by a safety profile that includes weight gain, peripheral edema, and increased risk of bone fracture[Sanyal 2010; Bril 2018; AASLD 2018; EASL 2016; Beltowski 2013]
    • Large randomized controlled trials have demonstrated improvement in histologic features of NAFLD with vitamin E[Lavine 2011; Sanyal 2010]

Action required